Skip to content

Search

Rapid Strep A testing unlocks missed infections, offering new path to prevent rheumatic fever

New research has revealed that molecular point-of-care testing (POCT) can significantly improve detection of Group A Streptococcal (Strep A) pharyngitis compared to laboratory culture – particularly in remote communities, where results can take up to seven days – unlocking a major opportunity to prevent rheumatic

Partnering with communities to reduce rheumatic heart disease in the Kimberley

The Kimberley has the highest rates of rheumatic heart disease (RHD) in Western Australia – but through the establishment of a new community-led, research-backed project known as END RHD Communities, there’s hope this will change.

Ending deadly heart disease finally within our sights

It's been a huge year for those working to eliminate rheumatic heart disease (RHD), with breakthroughs including $35M in funding to develop a Strep A vaccine.

Finding answers for Tenaya: from a sore throat to open-heart surgery

When Katrina took her daughter Tenaya to the local emergency department for the fourth time, she was determined she wouldn’t be leaving without answers.

Australia a key contributor to global commitment to end deadly rheumatic heart disease

The World Health Organisation resolution for global action to tackle rheumatic heart disease (RHD) will have significant implications for Australia, which has some of the highest rates of the disease in the world.

National honour for The Kids Director

Leading paediatrician, infectious diseases specialist and Executive Director of The Kids Research Institute Australia, Professor Jonathan Carapetis, has been recognised for his significant contribution towards medical research with the award of Member of the Order of Australia (AM).

Rheumatic Heart Disease

Rheumatic heart disease (RHD) is the most important cause of acquired cardiovascular disease in children and young adults. Virtually non-existent in most of Australia, it still predominantly affects Aboriginal communities.

Early rheumatic heart disease is a recognized intermediate on the pathway to advanced rheumatic heart disease

Rheumatic heart disease is a major cause of premature cardiovascular morbidity and mortality globally. Over the past decade, echocardiographic screening has changed our understanding of the natural history of RHD, revealing a high burden of clinically silent, mild RHD among people who cannot recall a history of preceding acute rheumatic fever. This viewpoint outlines the evidence that this earliest form of rheumatic heart disease, only detectable through echocardiographic screening, is an intermediate stage that many, but not all, individuals may pass through on the pathway to advanced rheumatic heart disease.

Determinants of secondary prophylaxis for childhood rheumatic heart disease in Ethiopia: A qualitative study of children and caregivers

Rheumatic heart disease remains a major public health challenge in Ethiopia, particularly among children. Monthly intramuscular benzathine penicillin G is the cornerstone of secondary prophylaxis, yet adherence and delivery are suboptimal. This study explores the lived experiences of children and adolescents with RHD, capturing their direct voices and those of their caregivers to understand determinants of secondary prophylaxis uptake.

Cardiovascular outcomes for Australian women with rheumatic heart disease during pregnancy: A retrospective linked data analysis, 2002–2017

Rheumatic heart disease (RHD) is the acquired autoimmune heart valve damage resulting from untreated infection with the Streptococcus pyogenes bacterium, which affects people experiencing socioeconomic disadvantage globally. This study measured RHD-associated major adverse cardiovascular events (MACE) and the increased risk associated with pregnancy among women diagnosed with RHD.